Press Releases< /span>
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Aug 5, 2022
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q2 2022 financial results on Thursday, August 11, 2022 after market close. The Company...
-
Jun 22, 2022
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") today announced that it held its annual and special meeting of shareholders earlier today and that all matters put forward before...
-
May 12, 2022
(All figures are in U.S. dollars) Drove 60% increase in EPS to $0.08 Demonstrated a focus on execution as EBITDA increased 38% to $3.1 million Total operating expenses declined 25% to $2.5 million...
-
May 9, 2022
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q1 2022 financial results on Thursday, May 12, 2022 after market close. The Company will...
-
Mar 22, 2022
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that the Company's partner, Moberg Pharma AB, ("Moberg Pharma") has submitted a regulatory filing for the next...
-
Mar 17, 2022
Demonstrated growth in FY 2021 as EBITDA increased 46% to $11.8 million Disciplined cost structure led to an 18% reduction in SG&A 81% increase in EPS to $0.29 in FY2021 Strengthened cash flow...
-
Mar 11, 2022
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial and operating results for the three and twelve months ended December 31, 2021...
-
Mar 10, 2022
Royalty agreement granting Sun Pharmaceutical Industries Inc. exclusive right to market, sell and distribute Absorica, Absorica AG and Absorica LD in the U.S. extended through December 31, 2026...
-
Nov 11, 2021
Revenue for nine months ended September 30, 2021increases 4.1% to $16.1 million Adjusted EBITDA1 for nine months ended September 30, 2021 increases to $9.8 million Basic EPS for the nine months ended
-
Nov 3, 2021
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q3 2021 financial results on Thursday, November 11, 2021. The company will hold a...
-
Sep 8, 2021
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, notice of Cipher's intention to renew...
-
Aug 12, 2021
Revenue increases 30% to $6.1 million, Adjusted EBITDA2 increases 40% to $4.1 million EPS increases 450% to $0.11 (CDN$0.141) Epuris revenue grows 63%, Absorica revenue grows 25% All figures in...
-
Aug 9, 2021
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q2 2021 financial results on Thursday, August 12, 2021. The company will hold a conference...
-
Jun 23, 2021
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") today announced the voting results for the election of directors at its Annual Meeting of Shareholders held earlier today. A...
-
May 13, 2021
Generates Adjusted EBITDA of $3.6 million and EPS of $0.05 (CDN$0.61) Excluding legal provision EPS was $0.10 (CDN$0.12) OAKVILLE, ON, May 13, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH)...
-
May 5, 2021
Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced it will release its Q1 2021 financial results after market close on Thursday, May 13, 2021. The company will hold...
-
Mar 25, 2021
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has received approval from the Toronto Stock Exchange ("TSX") to amend its normal course issuer bid...
-
Mar 18, 2021
Adjusted EBITDA increases 9% to $13.7 million and EPS increases 60% to $0.16 (CDN$0.211) for the full year OAKVILLE, ON, March 18, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or...
-
Mar 10, 2021
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q4 2020 financial results after the close on Thursday, March 18, 2021. The company will hold...
-
Feb 10, 2021
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it has entered into an exclusive co-promotion agreement (the "Agreement") with Verity Pharmaceuticals Inc. for...
-
Jan 15, 2021
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it has received an arbitration award in the previously announced dispute between the Company and Bausch Health...
-
Nov 12, 2020
Revenue Increases Sequentially to $4.9 million EBITDA2 was $2.7 million or 55% of net revenue OAKVILLE, ON, Nov. 12, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company")...
-
Nov 3, 2020
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q3 2020 financial results after the close on Thursday, November 12, 2020. The Company will...
-
Oct 8, 2020
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today the voting results for the election of directors at its Annual Meeting of Shareholders held earlier today. A...
-
Aug 12, 2020
Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, a Notice of Intention to Make a...